Sign in

Institute for Psychedelics and Neurotherapeutics

@ucdavisipn.bsky.social
136 followers 26 following 104 posts

Our mission is to advance our understanding of the basic neurobiology of psychedelics and translate this knowledge into safe and effective therapeutics

PostsRepliesMedia
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 05/10/2026
Check out this episode of Healthy Minds from @pbs.org from Brain & Behavior Research Foundation (BBRF). #UCDavisIPN @deolsonlab.bsky.social talks non-hallucinogenic neuroplastogens and more!
pbs.org
Healthy Minds With Dr. Jeffrey Borenstein | Psychedelic Drugs For Psychiatric Treatment | Season 11 | Episode 2
Neuroplastogens may treat depression, schizophrenia, anxiety, and dementia without hallucinations.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 16/09/2026
Congrats to #UCDavisIPN Director @deolsonlab.bsky.social, named in this year's Blavatnik National Awards for Young Scientists for work on how #psychedelics promote #neuroplasticity & engineering non-hallucinogenic analogues toward safer treatments for neuropsychiatric & neurodegenerative conditions.
blavatnikawards.org
David E. Olson | Blavatnik Awards for Young Scientists
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 08/09/2026
These next-generation compounds could open the door to safer, more effective antidepressants, antipsychotics, and anti-seizure agents, without the hallucinogenic side effects. Read the press release: lettersandsciencemag.ucdavis.edu/science-tech...
lettersandsciencemag.ucdavis.edu
Deconstructing LSD for Therapeutic Discoveries
University of California, Davis, researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects. In a new study, the researchers whittled away at LS...
001
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 08/09/2026
The work identifies which molecular features are necessary for LSD's activity at serotonin receptors, a key step toward designing new #LSD analogues with reduced hallucinogenic potential.
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 08/09/2026
#UCDavisIPN Director @deolsonlab.bsky.social , affiliates @tantillogroup.bsky.social and Oliver Fiehn, and their teams just published a new study in @pnas.org deconstructing the ergoline core of LSD. Read the study: www.pnas.org/doi/10.1073/...
pnas.org
Deconstruction of lysergic acid diethylamide | PNAS
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited syntheti...
121
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 04/09/2026
New clinical trial out of Toronto published in @jama.com found that IV #ketamine significantly reduced depression symptoms in people with treatment-resistant #bipolardepression, outperforming a placebo with no cases of mania or psychosis. Read more:
jamanetwork.com
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 02/09/2026
#UCDavisIPN Director @deolsonlab.bsky.social covers a lot of ground on @acs.org's Chain Reaction podcast. Find out more about ketamine as an anti-depressant, psychoplastogens, non-hallucinogenic psychedelic analogues, and zalsupindole! Listen or read here:
acs.org
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 10/08/2026
#UCDavisIPN Affiliate Danielle Stolzenberg weighs in on a new piece digging into why so many midlife women are turning to #microdosing mushrooms for #menopause symptoms. She notes that many women feel underserved by conventional care and are turning to experimental self-medication. Read more here:
theflowspace.com
The Midlife Microdosing Boom: Why Women Are Trying Magic Mushrooms
Why midlife women are microdosing psilocybin for menopause stress, focus and mood—and what experts say about safety and risks.
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 05/08/2026
Don't miss #UCDavisIPN affiliate @manvir.bsky.social's presentation at States of Consciousness this October. Check out the other speakers and register at psychedelics.berkeley.edu/soc-conference #StatesofConsciousness2026 @scipsychedelics.bsky.social
psychedelics.berkeley.edu
States of Consciousness: Psychedelic Discovery and the Edge of Uncertainty - UC Berkeley Center for the Science of Psychedelics
States of Consciousness (October 14-15, 2026) is a two-day multidisciplinary conference at UC Berkeley exploring the evolving questions and uncertainty around the study of consciousness through the le...
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 30/07/2026
This hints at how this new scaffold could sharpen drug design, and is a great example of fundamental synthetic #chemistry opening doors for drug discovery.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 30/07/2026
The team built an analog of a prostate cancer drug using this chemistry as proof of principle. Computational chemistry was used to interrogate the aromaticity and show that one stereoisomer of the enzalutamide analog makes extra contacts with the drug's protein target that the original drug misses.
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 30/07/2026
#UCDavisIPN Affiliates @tantillogroup.bsky.social and @shawshankrxn.bsky.social published a new way to build chiral aromatic 5-membered heterocycles, unlocking potential for replacing flat heteroarenes with tetrahedral stereogenic centers. Find out why it matters for #medicinalchemistry:
cen.acs.org
Reaction rounds up atoms into unusual cyclic compounds
Chiral aromatic heterocycles could be novel motifs in drug candidates
112
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 27/07/2026
From NIH's Zarate lab: a new study in Nature compared HNK, #psilocybin, LSD, and DOI in human stem cell-derived neurons. Despite hitting different receptors, all produced similar gene expression shifts, dipping at 6 hours then rebounding by 24 with increased synapse formation. Read the study:
nature.com
Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers - Molecular Psychiatry
Molecular Psychiatry - Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers
020
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 21/07/2026
#UCDavisIPN Affiliate Richard McKenney co-authored a new study in Science Magazine (Advances) revealing how the kinesin-1 protein switches on and off inside nerve cells. Learning more about these structures could influence future drug discovery. Read the press release: #neuroscience #ALS
ucdavis.edu
‘Enchanted Broomstick’ Protein Walks on Two Stubby Legs to Keep Our Nerve Cells Alive
A nerve cell resembles a vast tree with branches that communicate with thousands of other cells. To function, it depends on a motor protein that walks on two legs, hauling urgent cargo from the center...
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 26/05/2026
As #psilocybin and MDMA trials expand for #PTSD, #depression, and other conditions, and legal access grows across U.S. states, Lucy offers a scalable path to closing the facilitator shortage. Full interview above in @natureportfolio.nature.com.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 26/05/2026
Cognitive scientist Félix Schoeller and his team built an AI platform called Lucy that trains #psychedelic assisted therapy facilitators using thousands of anonymized real support calls, generating simulations of people in altered states so clinicians can practice before working with clients.
nature.com
How we’re using AI tools to improve psychedelic-drug research
Félix Schoeller’s team built a realistic artificial-intelligence chatbot to train facilitators needed for research into psychoactive drugs — and, ultimately, to improve public health.
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 19/05/2026
The #UCDavisIPN was featured on KCRA3 last week! Check out Director @deolsonlab.bsky.social discussing how non-hallucinogenic #psychedelic compounds like JRT could revolutionize mental health treatment for schizophrenia.
kcra.com
LSD-like drug and magnet therapy: Sacramento explores new treatments for depression
Doctors in Sacramento are using transcranial magnetic stimulation and experimental drugs inspired by psychedelics to address depression and other mental health challenges.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 21/04/2026
New from #UCDavisIPN Director @deolsonlab.bsky.social: R-MDDMA is a safer MDMA analogue that retains its therapeutic potential for promoting #neuroplasticity, facilitating fear extinction, and producing antidepressant-like effects, without the abuse liability, hyperthermia, or cardiac risks.
doi.org
R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD...
020
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 14/04/2026
#UCDavisIPN Director @deolsonlab.bsky.social weighed in on the risks of these self-regulated "clandestine chemists": without adequate testing, consumers have no way of knowing whether these products are free from toxins.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 14/04/2026
A new The Philadelphia Inquirer investigation found that smoke shops in the Philadelphia area are selling unregulated #psychedelic products, and the results are alarming. Lab tests revealed fabricated safety reports, banned hallucinogens, and synthetic compounds with unknown health effects.
inquirer.com
Some Philadelphia-area smoke shops sell unregulated psychedelics that often mislead customers
Philadelphia is a wonderland for unregulated “magic mushrooms.” Trip at your own risk.
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 09/04/2026
New research published in @natureportfolio.nature.com - Medicine out of @ucsanfrancisco.bsky.social reveals a shared brain signature across classic #psychedelics: flattened cortical hierarchy, increased subcortical-cortical coupling, and less "network disintegration" than previously thought.
nature.com
An international mega-analysis of psychedelic drug effects on brain circuit function - Nature Medicine
Analysis of neuroimaging datasets across five major psychedelics revealed a shared brain signature and provides a comprehensive insight into how these drugs reorganize brain architecture.
011
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 26/03/2026
Read about #UCDavisIPN Director @deolsonlab.bsky.social and his team's latest research published in @cellpress.bsky.social. With the labs of David Nagib and Mark Levin, the team utilized a new method of skeletal editing to convert LSD into a new analogue with lower hallucinogenic potential.
cell.com
Skeletal editing by iron-catalyzed carbene insertion of trichloromethanes
DeMuynck and colleagues describe a new, iron-catalyzed method for carbene insertion of trichloromethanes into a diverse range of indoles. By harnessing commercially available trichloromethane reagents...
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 13/03/2026
#UCDavisIPN Director @deolsonlab.bsky.social and Assoc. Director John Gray, are featured in a new @newyorker.com article exploring the science behind why mind-altering drugs (and non-hallucinogenic #psychedelic analogues) can have lasting therapeutic effects. Read the story here:
newyorker.com
Why Do Mind-Altering Drugs Make People Feel Better?
Scientists want to redesign psychedelics so that they don’t induce a trip—but they still improve mental health.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 11/03/2026
A new clinical trial in JAMA Network Open compares psilocybin-assisted therapy vs. nicotine patches for smoking cessation. Participants who received a single dose of #psilocybin alongside CBT had over 6× greater odds of quitting smoking at 6 months compared with those using nicotine patches.
jamanetwork.com
Psilocybin or Nicotine Patch for Smoking Cessation
This pilot randomized clinical trial compares prolonged smoking abstinence rates in smokers receiving psilocybin with those receiving the nicotine patch with both groups receiving manualized smoking c...
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 05/03/2026
This week in neurotherapeutics and women's health: A new study in @natureportfolio.nature.com - npj Women’s Health used genetic approaches to test whether targeting estrogen receptors affects Alzheimer’s risk, brain structure, depression, or anxiety. Read what they found here:
nature.com
Menopausal hormone therapy and risk of neuropsychiatric disease: a drug target Mendelian randomisation study - npj Women's Health
npj Women's Health - Menopausal hormone therapy and risk of neuropsychiatric disease: a drug target Mendelian randomisation study
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 03/03/2026
In the phase 1 CuRe Trial, placenta-derived mesenchymal stem cells were applied during in utero repair of myelomeningocele. Among the first six patients, there were no cell-related adverse events, no abnormal tissue growth, and successful reversal of hindbrain herniation on MRI.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 03/03/2026
#UCDavisIPN affiliate Aijun Wang and his team have published first-in-human results in @thelancet.com demonstrating the safety of a novel stem cell therapy delivered before birth for spina bifida.
thelancet.com
Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study
This first-in-human treatment consisting of allogeneic, live stem cells showed no cell-related adverse effects. The therapy was assessed as sufficiently safe to proceed with non-staggered enrolment of...
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 27/02/2026
They developed a platform called VESSEL to build artificial nanovesicles displaying individual EV surface proteins, one at a time. By stripping away the usual protein complexity of native vesicles, they could directly test which proteins influence neuronal repair.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 27/02/2026
#UCDavisIPN Affiliate Aijun Wang and his team released a new study in @acs.org - Nano highlighting how engineering simplified extracellular vesicle mimetics can help uncover which surface proteins actually drive neuroprotective effects. 1/2
pubs.acs.org
Prototyping Minimal Extracellular Vesicle Mimetics Using Cell-Free Synthesis
The many surface proteins on extracellular vesicles (EVs) allow them to target recipient cells and modulate cellular responses. Despite their importance, relating surface protein and EV function is challenging due to surface protein heterogeneity. Here, we create a bottom-up, cell-free protein-synthesis platform to engineer artificial nanovesicles (ANVs) that display different EV surface protein domains. The platform is termed VESSEL (Vesicle Engineering Systems using Synthetic Expression and Loading). The surface proteins are selected based on proteomics data of native EVs from placental mesenchymal stem cells (PMSCs). To create VESSEL, we establish a protein anchor based on the bacteria membrane protein Aquaporin-Z. This anchor allows the flexible and cell-free protein synthesis of 39 different EV surface protein domains, each anchoring into more than 108 ANVs per μL. Furthermore, we measure the ANVs using high-fidelity assays, including single-ANV flow cytometry, super-resolution imaging, and vesicle-based ELISA. Next, we show the impact of each EV surface protein on cellular uptake. Specifically, we find that certain EV surface protein domains govern ANV uptake into HEK293FT cells, explaining the variable observations in the field. We discovered new proteins, such as CADM1 and NPTN, that mediate high-efficiency cellular uptake. Additionally, five proteins were selected for our neuroprotection assay, where three proteins were significant in increasing SH-SY5Y neurite growth. Our work demonstrates a high-throughput cell-free synthesis platform for studying surface proteins of EVs. It enables the systematic interrogation of EV’s function as “signalosomes” and facilitates the designing of well-defined EV mimetics to mediate cellular function.
110
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 24/02/2026
You can also read the KCL press release here: www.kcl.ac.uk/news/ketamin...
kcl.ac.uk
Ketamine high not related to treatment success for people with alcohol use disorder, study finds | King's College London
The psychedelic effects recreational users often seek from taking ketamine do not predict the therapeutic benefits for people being treated for alcohol use disorder, according to new research from Kin...
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 24/02/2026
Out of @kingscollegelondon.bsky.social and @exeter.ac.uk comes new evidence that the intensity of the #ketamine “high” doesn’t predict treatment success for people with alcohol use disorder. What seems to matter more are the underlying neurobiological effects, not the subjective experience.
pubmed.ncbi.nlm.nih.gov
The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial - PubMed
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects appear to be broadly consistent across three repeated infusions. Ketamine-related reductions in alcohol consumption do not appear to be mediated by the acut …
120
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 04/02/2026
New research in @pnas.org offers fresh insight into how brain connections are lost in #Alzheimer’s disease. The study finds that C4d, a molecule linked to the immune system, increases with age and Alzheimer’s, and can directly trigger the removal of synapses, the connections between neurons.
pnas.org
C4d, a high-affinity LilrB2 ligand, is elevated in Alzheimer’s disease and mediates synapse pruning | PNAS
Synapse pruning sculpts neural circuits throughout life. The human Leukocyte immunoglobulin-like receptor type B2 (LilrB2)/murine Paired immunoglob...
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 03/02/2026
#UCDavisIPN Director @deolsonlab.bsky.social on efforts to bring ibogaine therapy to WA State: The potential for treating #addiction, #PTSD, and #TBI is compelling, but federal legality and limited clinical data remain real barriers. Promising therapies still need rigorous science and safety first.
thestranger.com
State Sen. Jesse Salomon Wants to Bring Ibogaine Therapy to Washington
State Sen. Jesse Salomon, Washington's mushrooms legislator, wants to broaden the state's psychedelic horizons with Ibogaine therapy, a drug that supposedly acts as an almost miracle balm for psychic ...
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 30/01/2026
This week in #psychedelic science: A new @natureportfolio.nature.com paper disentangles how psychedelics work at the 5-HT2A receptor. The study shows that Gi signaling drives hallucination-like effects, while Gq signaling underlies therapeutic outcomes. Read the study:
nature.com
Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling - Nature
Psychedelics and their non-hallucinogenic analogues were compared, revealing that serotonin 2A receptor (5-HT2AR)-mediated Gi signalling is essential for hallucinogenic effect, with the functional mec...
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 16/01/2026
This work provides a clear structural framework for designing more precise ion-channel therapeutics. These insights are especially relevant for neurological disorders where KCa2.2 modulation holds clinical promise.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 16/01/2026
New in @natureportfolio.nature.com - Communications from #UCDavisIPN Affiliate Heike Wulff: Researchers report the first high-resolution cryo-EM structures explaining how small-molecule activators selectively target the KCa2.2 potassium channel.
nature.com
Structural basis for the subtype-selectivity of KCa2.2 channel activators - Nature Communications
Activators of KCa2.2 channels constitute potential novel treatments for neurologic disorders. Here, authors report cryo-EM structures of activator-bound channels, providing a framework for structure-b...
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 09/01/2026
#UCDavisIPN affiliate Danielle Stolzenberg spoke with the Mind & Matter podcast about the neurobiology of maternal care and her research on psilocybin exposure during the postpartum period. Check it out!
mindandmatter.substack.com
Stress & Psilocybin: Effects on Maternal Care & Offspring Development | Danielle Stolzenberg | 270
Neurobiology of maternal care in mammals: hormonal influences, stress effects & a study on psilocybin's unexpected effects during the postpartum period.
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 07/01/2026
Check out the new research from #UCDavisIPN trainees Joseph Beckett and Trey Brasher, introducing a light-driven way to convert amino acids into psychedelic-inspired molecules. These compounds engage the serotonin system and may represent a new class of non-hallucinogenic neurotherapeutics.
lettersandsciencemag.ucdavis.edu
Creating Hallucination-free, Psychedelic-like Molecules by Shining Light on Life’s Basic Building Blocks
UC Davis researchers have developed a new method that uses light to transform amino acids — the building blocks of proteins — into molecules that are similar in structure to psychedelics and mimic the...
020
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 06/01/2026
Congratulations to #UCDavisIPN Affiliate and Brain and Behavior Research Foundation grant recipient Alex Nord and the team behind JRT, a non-hallucinogenic analogue of LSD. Their work has been named one of BBRF’s leading research achievements of 2025.
bbrfoundation.org
2025 Leading Research Achievements | Brain & Behavior Research Foundation
We are pleased to present you with the 2025 Leading Research Achievements by BBRF Grantees, Prize Winners & Scientific Council Members.
020
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 05/01/2026
#UCDavisIPN affiliate Richard Maddock published a meta-analysis that identified a difference in brain choline levels in people with anxiety versus those without. Maddock's team found that brain choline levels in people with anxiety were 8% lower than their non-anxious peers. Read the paper here:
nature.com
Transdiagnostic reduction in cortical choline-containing compounds in anxiety disorders: a 1H-magnetic resonance spectroscopy meta-analysis - Molecular Psychiatry
Molecular Psychiatry - Transdiagnostic reduction in cortical choline-containing compounds in anxiety disorders: a 1H-magnetic resonance spectroscopy meta-analysis
031
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 22/12/2025
Together, the findings highlight a promising new class of serotonin-targeting drugs that may preserve the benefits of psychedelics, such as antidepressant or neuroprotective effects, while minimizing perceptual changes.
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 22/12/2025
These novel compounds resemble known psychedelics, engage the brain’s serotonin system, and show therapeutic potential without triggering hallucinogenic behaviors.
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 22/12/2025
Their work introduces a new method to use UV light to convert simple amino acids—the building blocks of proteins—into previously difficult to access small molecules.
100
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 22/12/2025
#UCDavisIPN Affiliates and Ph.D. students Joseph Beckett and Trey Brasher, together with their research advisor and senior author Mark Mascal, have published new research in the Journal of the American Chemical Society using a light-driven chemical reaction to make psychedelic-inspired molecules.
pubs.acs.org
Transforming Amino Acids into Serotonin 5-HT2A Receptor Ligands Using Photochemistry
A light-induced cyclization via a radical spin-center shift process that results in the direct functionalization of the indole ring at the C4-position is developed into a practical method for the synt...
110
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 03/12/2025
Check out NatGeo's story on LSD as a treatment for anxiety and #depression. In the piece, #UCDavisIPN Director, @deolsonlab.bsky.social, highlights how JRT, the IPN's non-hallucinogenic #psychedelic analogue of LSD, "could be a game-changer" for expanding access to mental health treatments.
nationalgeographic.com
LSD for anxiety and depression? Some early studies show promise.
Researchers are investigating whether the drug could be used in mainstream medicine—with and without its hallucinatory effects.
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 02/12/2025
@thetransmitter.bsky.social named #UCDavisIPN affiliate @doctheagrif.bsky.social and former affiliate @tinakim-neuro.bsky.social as rising stars in the field of #neuroscience for 2025. Read more about their work on voltage gated ion channels and #psychedelic -responsive neurons here:
thetransmitter.org
The Transmitter’s Rising Stars of Neuroscience 2025
We recognize the outstanding achievements of 25 neuroscientists who stand to shape the field for years to come.
132
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 24/11/2025
Check out #UCDavisIPN Affiliate Danielle Stolzenberg on @drjodipawluski.bsky.social podcast "Mommy Brain Revisited." Danielle discusses just how much we have to learn about #psychedelics as a treatment for the mental health of new mothers and their offspring too. Listen here:
open.spotify.com
60. Psychedelics Postpartum
000
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 20/11/2025
#UCDavisIPN Affiliate @baleslab.bsky.social and Directors @deolsonlab.bsky.social and John Gray's teams' works were recognized in @thetransmitter.bsky.social list of the Buzziest Neuroscience Papers. Explore the full list and learn what makes these papers stand out: #Neuroscience #Psychedelics
thetransmitter.org
The buzziest neuroscience papers of 2023, 2024
The field took note of work on brain-computer interfaces for speech, the mechanism of psychedelics, defining hippocampal representations, and more.
150
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 05/11/2025
Attend Cure Addiction Now's forum and webinar to hear directly from leading scientists in the field. There are 3 ways to join - in person, online, or on-demand afterwards! To learn more and register, head to this link: cureaddictionnow.org/the-raw-trut...
010
Institute for Psychedelics and Neurotherapeutics @ucdavisipn.bsky.social · 28/10/2025
Patients in the Delix trial that were given zalsupindole saw a rapid and robust reduction in symptoms of MDD that lasted for 4 weeks or more—long after the drug was cleared from the body. Given the safety profile of zalsupindole, the FDA is even allowing for at home administration in future trials!
000